CENTANY Drug Patent Profile

When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	2
Patent Applications:	5,056
What excipients (inactive ingredients) are in CENTANY?	CENTANY excipients list
DailyMed Link:	CENTANY at DailyMed

Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
St. Louis Children's Hospital	Phase 2
Cook Children's Medical Center	Phase 2
University of Texas Southwestern Medical Center	Phase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	BX	RX	No	No

Expired US Patents for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	6,013,657

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0933081	Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin)
Canada	2259764	COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN)
Spain	2165723

CENTANY Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for CENTANY

Introduction to CENTANY

CENTANY, a brand name for the antibiotic mupirocin, is a topical ointment approved by the FDA for the treatment of certain skin infections. Here, we will delve into the market dynamics and financial trajectory of CENTANY, considering various factors that influence its position in the pharmaceutical market.

Market Segment: Topical Drug Delivery

CENTANY falls under the broader category of topical drug delivery, a market that has been experiencing significant growth. The global topical drug delivery market was estimated to be worth $207.4 billion in 2022 and is projected to reach $317.8 billion by 2027, growing at a CAGR of 8.9% from 2022 to 2027[1].

Product Category and Formulation

CENTANY is classified as a semi-solid formulation, specifically an ointment, which is one of the key product categories in the topical drug delivery market. Semi-solid formulations, including creams, ointments, lotions, gels, and pastes, are widely used due to their ease of application and effectiveness in treating skin conditions[1].

Facility of Use

The use of CENTANY is predominantly in home care settings, which accounted for the largest share of the topical drug delivery market. Home care settings offer advantages such as better convenience, improved medical adherence, and better treatment outcomes, contributing to the growth of this segment[1].

Geographical Market

North America, where CENTANY is approved and widely used, holds the largest share of the global topical drug delivery market. This region's large share can be attributed to the rising prevalence of target health conditions, the increasing preference for pain-free drug delivery solutions, and the high demand for self-administered drugs[1].

Regulatory Environment

CENTANY, approved by the FDA in 2002, operates within a stringent regulatory framework. The absence of a generic version in the United States indicates that the product maintains its market exclusivity, which can positively impact its financial performance. However, it is crucial to note that the lack of generic competition also means that patients may face higher costs, and there is a risk of counterfeit versions being sold through fraudulent online pharmacies[4].

Financial Performance and Market Dynamics

The financial trajectory of CENTANY is influenced by several market dynamics:

• Market Growth Drivers: The increasing prevalence of skin infections and the growing need for effective topical treatments drive the demand for products like CENTANY. Additionally, advancements in transdermal drug delivery systems and the preference for pain-free and self-administered treatments contribute to market growth[1].

• Competitive Landscape: While CENTANY does not have a generic equivalent in the U.S., it competes with other branded and generic topical antibiotics. The competitive landscape is dynamic, with continuous innovation and the introduction of new products that could potentially challenge CENTANY's market position.

• Pricing and Revenue: The revenue generated by CENTANY is part of the larger topical drug delivery market. The market's projected growth to $317.8 billion by 2027 indicates a favorable financial outlook for products in this category. However, specific revenue figures for CENTANY are not publicly disclosed, but its market exclusivity and established presence suggest a stable financial performance.

Impact of Economic and Health Trends

Economic and health trends also play a significant role in the financial trajectory of CENTANY:

• Economic Factors: Economic uncertainties and geopolitical challenges can impact the pharmaceutical industry, including the funding environment for biotech companies. However, established products like CENTANY are generally more resilient to such fluctuations[2].

• Health Trends: The increasing incidence of skin infections and the growing geriatric population, which often requires long-term therapy, are positive trends for CENTANY. These factors contribute to a steady demand for effective topical treatments[1].

Key Takeaways

• Market Growth: The topical drug delivery market, including CENTANY, is expected to grow significantly, driven by increasing demand for pain-free and self-administered treatments.
• Regulatory Exclusivity: The absence of a generic version in the U.S. maintains CENTANY's market exclusivity but also poses risks related to counterfeit products.
• Competitive Landscape: CENTANY operates in a competitive market with continuous innovation, but its established presence and lack of generic competition provide a stable financial outlook.
• Health and Economic Trends: Positive health trends and economic resilience support the financial performance of CENTANY.

FAQs

1. What is the current market size of the topical drug delivery market?

   • The global topical drug delivery market was estimated to be worth $207.4 billion in 2022[1].

2. Is there a generic version of CENTANY available?

   • No, there is currently no therapeutically equivalent generic version of CENTANY available in the United States[4].

3. What are the key drivers of the topical drug delivery market?

   • High incidence of burn injuries, increasing number of smokers, growing prevalence of diabetes, and advancements in transdermal drug delivery systems are key drivers[1].

4. Which region holds the largest share of the global topical drug delivery market?

   • North America holds the largest share of the global topical drug delivery market[1].

5. What is the projected growth rate of the topical drug delivery market?

   • The market is projected to grow at a CAGR of 8.9% from 2022 to 2027[1].

Cited Sources

1. MarketsandMarkets, "Topical Drug Delivery Market Growth, Drivers, and Opportunities"
2. Syncona, "Building a platform for long-term growth and impact - Syncona"
3. IQVIA, "Understanding the Dynamics of Drug Expenditure - IQVIA"
4. Drugs.com, "Generic Centany Availability - Drugs.com"